Systemic Scleroderma Clinical Trial
Official title:
Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment
The aim of the study is to compare the exposure to environmental and professional toxics by patients with systemic scleroderma and by patients not achieved by this pathology.
This study is based on a questionnaire. The data will be collected according a retrospective and prospective design : - at diagnostic of the disease - at the inclusion in the systemic scleroderma cohort - during the annual visit (in 2017-2018-2019-2020) ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03629002 -
BIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA
|
||
Terminated |
NCT00377455 -
Placebo Controlled Trial of Bosentan in Scleroderma Patients
|
Phase 2 | |
Completed |
NCT00278525 -
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
|
Phase 2 | |
Completed |
NCT00318188 -
Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis
|
N/A | |
Completed |
NCT03575156 -
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
|
N/A | |
Active, not recruiting |
NCT01413100 -
Scleroderma Treatment With Autologous Transplant (STAT) Study
|
Phase 2 | |
Completed |
NCT00622895 -
Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03816189 -
Role of Eosinophil in Fibrogenesis of Systemic Sclerosis
|
||
Completed |
NCT01295736 -
Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY
|
Phase 3 | |
Completed |
NCT02213705 -
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
|
Phase 1/Phase 2 | |
Recruiting |
NCT03508375 -
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
|
N/A | |
Active, not recruiting |
NCT01309997 -
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
|
Phase 2 | |
Completed |
NCT00697736 -
Cardiac Repercussion of Systemic Sclerodermias
|
N/A | |
Completed |
NCT02349009 -
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
|
Phase 1/Phase 2 | |
Completed |
NCT00318175 -
Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis
|
Phase 2 | |
Recruiting |
NCT03816345 -
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
|
Phase 1 | |
Recruiting |
NCT04380831 -
TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis
|
Early Phase 1 | |
Terminated |
NCT00628797 -
Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT05672992 -
Longitudinal Spatial Frequency Domain Imaging Study
|
N/A | |
Recruiting |
NCT05726630 -
Clinical Study of Divozilimab in Patients With Systemic Scleroderma
|
Phase 3 |